Ipamorelin vs Sermorelin: GHSR vs GHRH Pathway Comparison
Editorial Board
Research Division
Ipamorelin vs Sermorelin: Two Routes to GH-Axis Stimulation
Ipamorelin and sermorelin both engage growth-hormone-axis signaling, but they enter at different receptors. Ipamorelin is a ghrelin receptor (GHSR-1a) agonist. Sermorelin is a GHRH analog that acts upstream on pituitary GHRH receptors. Same endocrine output, different signaling checkpoints.
Side-by-Side
| Property | Ipamorelin | Sermorelin |
|---|---|---|
| Primary Target Receptor | GHSR-1a (ghrelin receptor) | GHRH receptor (pituitary) |
| Class | GH secretagogue peptide | Synthetic GHRH analog |
| Typical Research Framing | Pulse triggering via ghrelin pathway | Physiologic pituitary signaling support |
| Common Pairing Strategy | Often paired with GHRH analogs | Often paired with GHSR agonists |
| Focus in Protocol Design | Pulse amplitude and timing response | Axis regulation and baseline support |
Different Receptors, Same Endocrine Axis
Sermorelin works through GHRH-receptor pathways on pituitary somatotrophs — it is a fragment analog of endogenous GHRH. Ipamorelin activates GHSR-1a (the ghrelin receptor) to stimulate GH pulse release through a separate route. Co-activation of these two pathways can produce additive pulse behavior without forcing a single receptor system to carry the full signaling burden, which is why the pair appears so often in stack protocols.
A distinguishing feature of ipamorelin (versus older GHRPs like GHRP-6 and GHRP-2) is its selectivity: less activity at non-GH axes, and consequently less appetite or cortisol confounding in study interpretation.
How to Select the Right Comparator
Let receptor intent lead selection:
- Choose sermorelin as anchor when modeling GHRH-like pituitary stimulation with emphasis on endocrine-physiology alignment.
- Choose ipamorelin as anchor when studying ghrelin-pathway pulse dynamics or stack-response analysis.
In both cases, observed outcomes depend on circadian timing, baseline IGF-1, and protocol duration — these factors shape results independent of compound identity. See the CJC / Mod GRF / sermorelin family guide and ipamorelin vs CJC-1295 comparison for related framings.
Bottom Line
Ipamorelin and sermorelin are not interchangeable — they hit different receptors. They are often complementary because those receptors converge on the same pulse output. Good research design treats this as a pathway question first, and a dosing question second.
Educational content only. Not medical advice.
Evidence & Citation Trail
Peer-reviewed references surfaced from the directly related peptide entities covered in this guide. This makes the page easier to verify, compare, and cite in answer engines.
Ipamorelin, the first selective growth hormone secretagogue
Ipamorelin • Raun K, et al. • Eur J Endocrinol (1998)
DOI: 10.1530/eje.0.1390552Sermorelin: a growth hormone-releasing hormone analog
Sermorelin • Thorner MO, et al. • J Clin Endocrinol Metab (1993)
DOI: 10.1210/jcem.77.5.8077320Hexarelin: a growth hormone-releasing peptide
Hexarelin • Deghenghi R, et al. • J Endocrinol Invest (1994)
DOI: 10.1007/BF03347720Explore in the Library
Answer-First FAQ
Direct questions and short answers designed for both reader clarity and answer-engine extraction.
Is ipamorelin the same as sermorelin?
No. Ipamorelin is primarily a ghrelin receptor (GHSR-1a) agonist. Sermorelin is a GHRH analog. Both can increase GH-axis activity, but through different receptors and for different research purposes.
Can they be combined in a research protocol?
Yes. Combination is common in GH-axis research because GHSR and GHRH signaling can be complementary. Researchers should still control for timing, dosing strategy, and endpoint definition.
Continue Exploring
Research-grade peptides with third-party testing and certificate of analysis.
Shop Peptides